CAR T cells for HER2-positive metastatic breast cancer
Part of Cancer, Skin clinical trials.
This trial tests a new type of immune cell therapy (CAR T cells) that targets two markers on cancer cells: TRAIL-R2 and HER2. It is for people with advanced or recurrent HER2-positive breast cancer that has not been stopped by standard treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 80 years old.
- You must have been diagnosed with HER2-positive breast cancer that has spread or cannot be removed by surgery.
- Your cancer must have gotten worse after at least one standard treatment.
- You must have a tumor sample showing HER2 levels of 1+, 2+, or 3+ by a special test (IHC).
- You must have adequate organ function (liver, kidneys, heart, and lungs) and be in fairly good overall health (ECOG score 0-2).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment using your own immune cells, modified to target a protein called B7-H3 on triple-negative breast cancer cells. It may help if other treatments haven't worked.
This trial tests a personalized immune-cell treatment (CAR T) built from your own blood lymphocytes. It targets cancers that show a marker called CD70, aiming to slow or stop the cancer when other treatments didn’t work.
This Phase 1 study tests a personalized immune-cell treatment (HER2 CAR T cells) given with an immune “checkpoint” medicine (pembrolizumab or another checkpoint blocker) to shrink advanced HER2-positive sarcoma. It may help patients whose cancer is progressing or coming back after prior treatment.
This Phase 1 trial tests CAR T cells made from your own immune cells to target advanced breast cancer. The cells are designed to recognize a specific cancer marker (called MUC1*), with the goal of shrinking tumors or keeping them under control.
This trial tests a new type of immunotherapy called CAR-T cells that are designed to attack cancer cells that have a high amount of a protein called HER2. It is for people with advanced solid tumors (like certain breast, stomach, or lung cancers) that have not responded to standard treatments.
This trial tests a new type of cell therapy (CAR-T cells) combined with a drug called trastuzumab (Herceptin) for HER2-positive advanced cancers, especially breast cancer. It aims to see if this combination can shrink or slow the tumor when other treatments have stopped working.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.